AU2020346057B2 - Thyroid hormone receptor beta agonist compounds - Google Patents

Thyroid hormone receptor beta agonist compounds

Info

Publication number
AU2020346057B2
AU2020346057B2 AU2020346057A AU2020346057A AU2020346057B2 AU 2020346057 B2 AU2020346057 B2 AU 2020346057B2 AU 2020346057 A AU2020346057 A AU 2020346057A AU 2020346057 A AU2020346057 A AU 2020346057A AU 2020346057 B2 AU2020346057 B2 AU 2020346057B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
formula
pharmaceutically acceptable
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020346057A
Other languages
English (en)
Other versions
AU2020346057A1 (en
Inventor
Randall HALCOMB
Thorsten A. Kirschberg
F. Anthony Romero
Yingzi XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of AU2020346057A1 publication Critical patent/AU2020346057A1/en
Application granted granted Critical
Publication of AU2020346057B2 publication Critical patent/AU2020346057B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020346057A 2019-09-12 2020-09-11 Thyroid hormone receptor beta agonist compounds Active AU2020346057B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899581P 2019-09-12 2019-09-12
US62/899,581 2019-09-12
PCT/US2020/050497 WO2021050945A1 (en) 2019-09-12 2020-09-11 Thyroid hormone receptor beta agonist compounds

Publications (2)

Publication Number Publication Date
AU2020346057A1 AU2020346057A1 (en) 2022-04-21
AU2020346057B2 true AU2020346057B2 (en) 2026-07-16

Family

ID=74866716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020346057A Active AU2020346057B2 (en) 2019-09-12 2020-09-11 Thyroid hormone receptor beta agonist compounds

Country Status (7)

Country Link
US (1) US12398127B2 (cg-RX-API-DMAC7.html)
EP (1) EP4028008A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022548250A (cg-RX-API-DMAC7.html)
CN (1) CN114375193B (cg-RX-API-DMAC7.html)
AU (1) AU2020346057B2 (cg-RX-API-DMAC7.html)
CA (1) CA3154391A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021050945A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
KR20230123928A (ko) 2020-11-06 2023-08-24 알리고스 테라퓨틱스 인코포레이티드 갑상선 호르몬 수용체 베타(tr-베타) 작용제로서의 비사이클릭 피리다지논
CN116940566A (zh) * 2021-03-19 2023-10-24 南京明德新药研发有限公司 双环吡啶酮类化合物及其应用
US20240239761A1 (en) * 2021-03-19 2024-07-18 Medshine Discovery Inc. Bicyclic phenol compounds and use thereof
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807674B2 (en) * 2005-07-21 2010-10-05 Hoffmann-La Roche Inc. Thyroid hormone analogs
US20150368205A1 (en) * 2011-11-30 2015-12-24 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Poly (adp-ribose) polymerase inhibitor
WO2020041741A1 (en) * 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197307A (en) 1977-04-12 1980-04-08 Ciba-Geigy Corporation 2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents
EP0377903A3 (de) 1989-01-09 1991-07-17 Bayer Ag Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
WO2002051805A1 (de) 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate
CA2473162A1 (en) 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
FR2882750B1 (fr) 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
GB0608724D0 (en) 2006-05-03 2006-06-14 Karobio Ab Novel Pharmaceutical Compositions
GB0610322D0 (en) 2006-05-24 2006-07-05 Karobio Ab Novel pharmaceutical compositions
WO2008130637A1 (en) 2007-04-18 2008-10-30 New York University Hydrazide compounds as thyroid hormone receptor modulators and uses thereof
SI2170403T1 (sl) 2007-06-27 2014-07-31 Quark Pharmaceuticals, Inc. Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
FR2933979B1 (fr) 2008-07-15 2012-08-24 Pf Medicament Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
KR101396606B1 (ko) 2009-04-20 2014-05-16 미쓰비시 타나베 파마 코퍼레이션 신규 갑상선 호르몬 β 수용체 작동약
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
EA023521B1 (ru) 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
CN102898377B (zh) 2012-02-14 2016-01-20 南京圣和药业股份有限公司 一类酞嗪酮衍生物及其用途
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
CA2944139C (en) 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
CN105477636B (zh) 2015-10-16 2019-09-17 厦门大学 使用阿维菌素及其衍生物治疗代谢疾病的方法
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ROR-γ調節劑
MX2018011813A (es) 2016-03-28 2019-01-24 Intercept Pharmaceuticals Inc Medicina obtenida mediante la combinacion de agonista fxr y arb.
PL3435996T3 (pl) 2016-03-31 2025-07-28 Genfit Elafibranor do zastosowania w leczeniu pierwotnego zapalenia dróg żółciowych
MX2018014024A (es) 2016-05-25 2019-08-29 Akarna Therapeutics Ltd Terapias de combinación con moduladores del receptor x farnesoide (fxr).
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
MX394463B (es) * 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
CA3041169A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
WO2018103624A1 (zh) 2016-12-06 2018-06-14 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
JP7618384B2 (ja) 2017-02-21 2025-01-21 ジェンフィ Pparアゴニストとfxrアゴニストとの組合せ
SG11201907673YA (en) 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
WO2018170173A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CA3058542A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
WO2018208707A1 (en) 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US20210121493A1 (en) 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
SG11202000748TA (en) 2017-08-25 2020-03-30 Genfit Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
WO2019053235A1 (en) 2017-09-15 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
EP3684954B1 (en) 2017-09-18 2025-11-26 Genfit Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
US11168079B2 (en) 2017-11-01 2021-11-09 Bristol-Myers Squibb Company Alkene compounds as farnesoid x receptor modulators
US20200340060A1 (en) 2017-11-13 2020-10-29 Gilead Sciences, Inc. Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
KR20210002573A (ko) 2018-04-24 2021-01-08 주식회사 피에이치파마 간 질환에 호중구 엘라스타제 저해제의 사용
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
EP3844156A4 (en) 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. TREATMENT OF LIVER DISEASES
NZ773110A (en) 2018-09-18 2024-11-29 Terns Inc Compounds for treating certain leukemias
US20220047553A1 (en) 2018-09-18 2022-02-17 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN119552152A (zh) 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
CN111484481A (zh) 2019-01-26 2020-08-04 察略盛医药科技(上海)有限公司 哒嗪酮类衍生物、其制备方法及其在医药上的用途
CN119431265A (zh) 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
WO2020228577A1 (zh) 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2020239076A1 (zh) 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
TW202114672A (zh) 2019-07-23 2021-04-16 瑞士商諾華公司 使用fxr促效劑的肝臟疾病之組合治療
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021121210A1 (zh) 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
WO2021231646A1 (en) 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
WO2021231644A1 (en) 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
US20220135540A1 (en) 2020-10-15 2022-05-05 Eli Lilly And Company Polymorphs of an fxr agonist
CN114437034A (zh) 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
JP2024510935A (ja) 2021-03-03 2024-03-12 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
US20240239761A1 (en) 2021-03-19 2024-07-18 Medshine Discovery Inc. Bicyclic phenol compounds and use thereof
US20230181583A1 (en) 2021-11-11 2023-06-15 Terns Pharmaceuticals, Inc. Treating liver disorders with an ssao inhibitor
MX2024005647A (es) 2021-11-11 2024-05-24 Terns Pharmaceuticals Inc Tratamiento de trastornos hepaticos con un agonista del thr-\03b2.
AU2022387121A1 (en) 2021-11-11 2024-06-20 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
WO2023220404A1 (en) 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Treatment of non-alcoholic steatohepatitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807674B2 (en) * 2005-07-21 2010-10-05 Hoffmann-La Roche Inc. Thyroid hormone analogs
US20150368205A1 (en) * 2011-11-30 2015-12-24 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Poly (adp-ribose) polymerase inhibitor
WO2020041741A1 (en) * 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds

Also Published As

Publication number Publication date
WO2021050945A1 (en) 2021-03-18
JP2022548250A (ja) 2022-11-17
US20220356177A1 (en) 2022-11-10
CN114375193A (zh) 2022-04-19
AU2020346057A1 (en) 2022-04-21
EP4028008A1 (en) 2022-07-20
US12398127B2 (en) 2025-08-26
CN114375193B (zh) 2024-05-14
JP2026027279A (ja) 2026-02-18
CA3154391A1 (en) 2021-03-18
EP4028008A4 (en) 2023-09-13